Helping achieve access:


  • Click here for detailed information about Medicare coverage (certain coverage limitations apply)
  • Reimbursed by many private insurance plans
  • Our Patient Advocates Team is available to assist your patients in the navigation of their experience with Biotheranostics. We will maintain contact with the patient to help educate and update throughout the process. Assists with:
    • Understanding of BCI billing policies
    • Applicability and enrollment into appropriate financial assistance programs
  • We offer a patient assistance program which alleviates the economic burden for many patients

Biotheranostics' Patient Advocates Team
Phone: 1-844-319-8111
Hours: M-F from 7AM-4PM (PST)

ICD-10 codes for BCI test requisition forms

All BCI Test Requisition Forms must include an ICD-10 code

  • 174.0 Malignant neoplasm of nipple and areola of female breast
  • 174.1 Maligtnant neoplasm of central portion of female breast
  • 174.2 Malignant neoplasm of upper-inner quadrant of female breast
  • 174.3 Malignant neoplasm of lower-inner quadrant of female breast
  • 174.4 Malignant neoplasm of upper-outer quadrant of female breast
  • 174.5 Malignant neoplasm of lower-outer quadrant of female breast
  • 174.6 Malignant neoplasm of axillary tail of female breast
  • 174.8 Malignant neoplasm of other specified sites of female breast
  • 174.9 Malignant neoplasm of breast (female) unspecified site
  • V86.0 Estrogen receptor positive status (ER+)

Biotheranostics, Inc. does not recommend diagnosis codes and will only submit diagnosis information provided to us by the ordering physician/physician’s staff

References
  1. Gustavesen G, et al. Am J Manag Care. 2014;20:e302-e310.
Breast Cancer Index Intended Use and Limitations

The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings.

This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.